Prevention of secondary hyperparathyroidism in hemodialysis patients: The key role of native vitamin D supplementation

Hemodialysis International

Volumn 14, Issue 4, 2010, Pages 486-491

  Jean, G ^a   Vanel, T ^a   Terrat, J C ^a   Chazot, C ^a  

^a Centre de Rein Artificiel de Tassin   (France)

Author keywords

Cinacalcet; Hemodialysis; Hyperparathyroidism; Parathyroidectomy; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; LANTHANUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

AGED; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PREVALENCE; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

AGED; CALCIMIMETIC AGENTS; DIETARY SUPPLEMENTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROIDECTOMY; PROSPECTIVE STUDIES; RENAL DIALYSIS; VITAMIN D;

EID: 77958581306     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00472.x     Document Type: Article

References (35)

1. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004; 44:34-38.
2. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42:1-201.
3. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int. 2006; 70:345-350.
4. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008; 73:771-777.
5. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26:622-631.
6. KDIGO C-M. Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76:S1-S130.
7. Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ. Relationship between vitamin d status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology. 2008; 13:63-67.
8. De Francisco AL. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther. 2004; 26:1976-1993.
9. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73:1296-1302.
10. Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and looser's zones independent of calcitriol? Kidney Int. 1999; 55:2169-2177.
11. Gomez-Alonso C, Naves-Diaz ML, Fernandez-Martin JL, Diaz-Lopez JB, Fernandez-Coto MT, Cannata-Andia JB. Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. Kidney Int. 2003; 85 (Suppl):S44-S48.
12. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68:1793-1800.
13. Urena P, Jacobson SH, Zitt E, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice-The echo observational study. Nephrol Dial Transplant. 2009; 24:2852-2859.
14. Drueke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin d derivatives. Clin J Am Soc Nephrol. 2009; 4:234-241.
15. Messa P, Macario F, Yaqoob M, et al. The optima study: Assessing a new cinacalcet (sensipar/mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008; 3:36-45.
16. Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kid Dis. 2009; 53:408-416.
17. Jean G, Terrat J-C, Vanel T, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: Effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008; 23:3670-3676.
18. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr. 2008; 18:395-399.
19. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009; 24:3799-3905.
20. Jean G, Terrat JC, Vanel T, et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: Evolution of serum 1, 25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract. 2008; 110:c58-c65.
21. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006; 70:654-659.
22. Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki C. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol Dial Transplant. 1994; 9:1751-1758.
23. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha, 25-dihydroxyvitamin D3: Implications in cell growth and differentiation. Endocr Rev. 2002; 23:763-786.
24. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004; 80:1678S-1688S.
25. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int. 2005; 95 (Suppl):S37-S42.
26. Visser M, Deeg DJH, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The longitudinal aging study amsterdam. J Clin Endocrinol Metab. 2003; 88:5766-5772.
27. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: A meta-analysis. JAMA. 2004; 291:1999-2006.
28. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18:613-620.
29. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72:1004-1013.
30. Coen G, Mantella D, Manni M, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005; 68:1840-1848.
31. Slatopolsky E, Delmez JA Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996; 11 (Suppl 3):130-135.
32. Schaefer K. Unsatisfactory control of serum phosphate: Why is it so common and what can be done? Nephrol Dial Transplant. 1994; 9:1366-1367.
33. Jean G, Chazot C, Charra B. Biological evolution of renal osteodystrophy after decreasing dialysate calcium from 1.75 to 1.6 mmol/L. Clin Nephrol. 2002; 57:91-92.
34. Fabretti F, Calabrese V, Fornasari V, Poletti I. Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol. 1991; 105:562-567.
35. Jean G, Vanel T, Terrat JC, et al. Treating mineral metabolism disorders in patients undergoing long hemodialysis: A search for an optimal strategy. Hemodial Int. 2009; 13:526-532.